Problem

Pando Bioscience addresses the slow, expensive, and technically difficult process of discovering and optimizing enzymes for pharmaceutical manufacturing, diagnostics, and life-science tools. Conventional enzyme engineering requires testing relatively small numbers of variants and often optimizes one property at a time, while customers need combinations of activity, selectivity, stability, fidelity, processivity, and freedom to operate. Pando says its platform screens 1,000-fold more enzymes, 75% faster, and 80% cheaper than traditional methods, targeting the cost and productivity constraints that limit enzyme-based processes.

The clearest use case is pharmaceutical biocatalysis: Pando reports replacing 11 chemical manufacturing steps with one enzymatic step, projecting a 50% reduction in manufacturing costs and a $24 million annual improvement in the customer’s profit margin. In diagnostics and sequencing, the corresponding pain is enzyme performance—for example, insufficient thermal stability, sensitivity, fidelity, or processivity—which can limit assay performance and commercial expansion.

Product / Service

Pando combines generative AI with an in-house, droplet-based ultra-high-throughput screening platform. Its models design mutations intended to improve multiple enzyme properties simultaneously; candidate DNA is synthesized and tested experimentally, with the resulting performance data fed back into the model for iterative learning. Pando says this design-build-test-learn cycle can be completed in roughly one month, rather than relying solely on in-silico predictions or slow conventional experimentation.

The company sells both custom programs and proprietary enzyme products. Its services cover small-molecule biocatalysis as well as DNA/RNA-modifying enzymes for sequencing, amplification, synthesis, and diagnostics, with an emphasis on enzymes that are free to operate and avoid crowded prior-art landscapes. Its product portfolio includes engineered Phi29 polymerases such as PD-Phi29 and Saiyan-Phi29, positioned around higher activity, thermostability, fidelity, processivity, and reduced error rates; products can be purchased directly, while custom discovery and engineering are offered through partnership engagements.

Market

Pando operates at the intersection of generative AI, synthetic biology, enzyme engineering, pharmaceutical biocatalysis, diagnostics, and molecular-biology tools. Its adjacent competitive set includes AI-enabled protein and enzyme-design companies such as Biomatter and Cradle, broader synthetic-biology platforms such as Ginkgo Bioworks, and established biocatalyst-optimization providers such as Codexis. Pando’s differentiation is the combination of multi-property generative design, unusually high-throughput experimental screening, and a focus on commercially useful, freedom-to-operate enzymes rather than purely computational designs.

The company appears to be beyond the laboratory proof-of-concept stage but remains an early-stage business. Pando was founded in 2022, joined Y Combinator’s Winter 2023 batch, and was listed as active with a five-person Boston team. It reports customer collaborations in both pharma manufacturing and diagnostics, including the 11-step-to-one-step biocatalysis case and a diagnostic enzyme improved for thermal stability and sensitivity. It also lists commercial-ready PD-Phi29 product availability through Fortis Life Sciences, although the public materials reviewed do not disclose revenue, customer names, or a larger financing history.